Special Issue "Uremic Toxins and Urinary Acute Kidney Injury Biomarkers"
Deadline for manuscript submissions: 31 December 2021.
Interests: uremic toxins; analytical methods; bioanalysis; metabolomics
Uremic toxins are compounds that are usually excreted by the kidneys. In renal failure they accumulate and exert uremic effects, interacting negatively with normal biological functions. Their increased level can cause chronic kidney disease (CKD) progression and is linked to cardiovascular events and mortality. Unfortunately, current conventional dialysis treatment ineffectively removes a number of uremic toxins, mainly due to the large molecular size and high protein affinity. The adverse effects of uremic toxins are related to oxidative stress, inflammation, fibrosis, neurotoxicity, propensity to infection, chronic kidney disease/metabolic bone disease, insulin resistance, and thrombogenicity. However, their harmful action is not yet fully understood. Since the amount of research on uremic toxins in acute kidney injury (AKI) is scarce, we encourage researchers to identify which solutes might impact patient outcomes in AKI, so that pharmacological or renal replacement therapy can be targeted to neutralize these substances.
AKI is related to high mortality, and its diagnosis and prediction remains a challenge. New methods of urine examination have been applied in recent years, including metabolomics, proteomics, transcriptomics, and genomics. As a result, novel biomarkers of AKI were proposed. Since several studies have shown their higher increase not only in AKI, but also in CKD, the search for a new AKI biomarker is ongoing.
The focus of this Special Issue is on uremic toxins and urinary acute kidney injury biomarkers. Submissions are welcome on the following topics:
- Identification of novel uremic toxins and acute kidney injury markers for diagnosis and prognosis in AKI and CKD. Relation between uremic toxins and urinary AKI biomarkers.
- Level of uremic toxins in different pathological and physiological states, especially in AKI.
- Novel effects and molecular mechanisms of action of uremic toxins on animals, various organs, tissues, and cells, especially related to kidney injury and organ disfunction observed in AKI (heart, lungs, liver, intestines, and brain).
Dr. Joanna Giebułtowicz
Dr. Wojciech Wołyniec
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- acute kidney injury
- chronic kidney disease
- renal replacement therapy
- gut–kidney axis
- glomerular filtration rate
- renal tubular dysfunction
- renal enzymes
- uremic toxicity
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Uremic Toxins and Urinary Acute Kidney Injury Biomarker
Authors: Jing Zhang; Fang Liu; Yiming Li; Zhiyong Peng
Affiliation: Dept. of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China
Abstract: Acute kidney injury (AKI) is described as a relatively common complication in ICU. However, there are no approved biomarkers that can properly identify proximal tubular injury while routine assessments lack sensitivity. The novel urinary markers of AKI are: neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), transforming growth factor beta-1, retionol-binding protein, cystatin C (Cyst-C), interleukin 18, liver-fatty-acid-binding protein, uromodulin, clusterin, and trefoil factor 3. Some of them have been demonstrated to predict the clinical outcomes of AKI, such as the need for initiation of dialysis and mortality. In this review, we focus on the current new AKI risk biomarkers, innovative diagnostic approaches, and future research direction